X-Linked Adrenoleukodystrophy: Why Newborn Screening for X-ALD Could Save Lives

What is X-linked adrenoleukodystrophy?

X-linked adrenoleukodystrophy (X-ALD) is a rare genetic metabolic disorder caused by mutations in the ABCD1 gene, which encodes a peroxisomal transporter protein essential for the import of very-long-chain fatty acids (VLCFAs) into peroxisomes for oxidation. Without functional ABCD1, VLCFAs accumulate to toxic levels in the adrenal cortex, nervous system, and other tissues. The hallmark biochemical signature of X-ALD is the accumulation of 24:6 and 26:0 VLCFAs, detected as elevated lysophosphatidylcholine-VLCFA (LPC-VLCFA) in dried blood spots.

X-ALD is the most common peroxisomal disorder, affecting approximately 1 in 20,000 to 1 in 50,000 males. Female carriers, who have one mutated X chromosome, typically show milder phenotypes due to X-inactivation, though some become symptomatic. The clinical presentations vary widely — from asymptomatic biochemical carriers to rapidly progressive cerebral forms in childhood — making early diagnosis critical.

The biochemistry: How VLCFAs accumulate and cause disease

Peroxisomes are essential organelles that perform the initial oxidation of VLCFAs (carbon chains longer than 20 atoms). When ABCD1 is defective, these substrates cannot enter peroxisomes and instead accumulate in the blood, brain, and adrenal tissue. The toxic effects include demyelination (loss of myelin insulation around nerve axons), adrenocortical necrosis, and neuroinflammation. LPC-VLCFA, a metabolite of accumulated VLCFAs, serves as the most sensitive and specific biomarker for X-ALD screening in newborn blood spots. A single abnormal LPC-VLCFA measurement has >99% specificity and sensitivity for detecting X-ALD in males.

Clinical phenotypes of X-ALD

Childhood cerebral X-ALD (ccX-ALD) accounts for 30-40% of cases. It typically presents between ages 5-12 with rapid cognitive decline, seizures, visual disturbances, and progressive neurological deterioration leading to vegetative state or death within months to years if untreated.

Adrenomyeloneuropathy (AMN), the most common adult phenotype (40-50% of cases), emerges in the third or fourth decade with progressive spastic paraparesis, sensory neuropathy, and adrenocortical dysfunction — progressing over years but leading to disability.

Addison-only phenotype affects 10-15% of males, manifesting as isolated adrenocortical insufficiency without neurological involvement, though progression to cerebral disease can occur unpredictably.

This phenotypic heterogeneity — occurring even in the same family with identical mutations — remains incompletely understood. However, early identification before symptom onset enables preventive intervention.

The critical window: Why early detection saves lives

The key therapeutic intervention for childhood cerebral X-ALD is haematopoietic stem cell transplantation (HSCT), which halts neurological progression if performed before significant neurological damage accrues. Studies show that HSCT before white matter involvement becomes severe can stabilise or improve outcomes, whereas transplantation after neurological symptoms develop is often ineffective. This narrow window — often before symptoms appear — underscores why newborn screening is transformative.

For asymptomatic males identified through newborn screening, regular imaging and biochemical monitoring allow early HSCT before cerebral disease manifests, offering a chance at normal or near-normal life. For adults with AMN, close adrenocortical monitoring and bone marrow transplantation during early neurological stages can also provide benefit.

LPC-VLCFA testing from dried blood spots

At Masdiag, LPC-VLCFA is quantified using LC-MS/MS from a single dried blood spot sample, the same collection method used for routine newborn screening. The test measures the plasma concentration of lysophosphatidylcholine-VLCFA (LPC-26:0), a more specific marker than total VLCFA alone. A single elevated result in a male or a consistently elevated result in a female warrants confirmatory testing and gene sequencing.

The advantages of DBS-based LPC-VLCFA screening are clear: the blood spot is non-invasive, stable during storage, and easily integrated into existing newborn screening algorithms. The test can identify affected males before any clinical symptom, enabling immediate referral for HSCT evaluation and discussion of gene therapy options.

Global push for X-ALD newborn screening inclusion

Several countries, including the United States (through Select Committee recommendations) and the United Kingdom, are implementing or considering X-ALD in universal newborn screening panels. The rationale is compelling: early detection prevents irreversible neurological damage, HSCT is curative if performed early, and the biomarker (LPC-VLCFA) is highly specific and robust. Screening programmes in Switzerland, Belgium, and other nations have already identified previously undiagnosed boys, confirming that X-ALD is more common than previously recognised and that many affected individuals would have experienced catastrophic neurological deterioration without early intervention.

Female carriers: A sometimes-overlooked group

Heterozygous females carry one mutated X chromosome but, due to X-inactivation (random silencing of one X chromosome in each cell), typically have milder phenotypes or remain asymptomatic. However, skewed X-inactivation in some females can lead to symptomatic disease. All female relatives of affected males should undergo LPC-VLCFA testing. Some affected females benefit from early HSCT or close neurological surveillance, particularly if white matter changes are detected on imaging.